Tampa, Florida Clinical Trials

A listing of Tampa, Florida clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 65 clinical trials
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis (FREVIVA)  

The purpose of this randomized, double-blind, placebo-controlled, parallel group study is to determine the efficacy of frexalimab in delaying the disability progression and the safety up to approximately 51 months administration of study intervention compared to placebo in male and female participants with nrSPMS (aged 18 to 60 years at …

MS & Neuromuscular Center of Excellence Site Number : 8400015
 (8.6 away)
  • 0 views
  • 04 Mar, 2025
  • +58 other locations
A Study Evaluating The Safety Tolerability Pharmacokinetics And Efficacy Of Venetoclax In Combination With Atezolizumab Carboplatin And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).

A study consisting of a dose-escalation phase and a dose-expansion phase to evaluate the safety, tolerability, pharmacokinetics, and efficacy of venetoclax in combination with atezolizumab, carboplatin, and etoposide.

atezolizumab
granulocyte colony stimulating factor
chemotherapy regimen
measurable disease
extensive stage small cell lung cancer
Moffitt Cancer Center
 (9.4 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +15 other locations
A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms

Hidradenitis suppurativa (HS) is an inflammatory skin disease that causes painful lesions in the axilla (underarm), inguinal (groin) and anogenital (anal and genital) regions. This study will evaluate how well upadacitinib compared to placebo (no medicine) works to treat hidradenitis suppurativa (HS) in adult participants with moderate to severe disease. …

ForCare Clinical Research /ID# 218013
 (9.2 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +27 other locations
Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor SAR442168

Primary Objective: To assess efficacy of daily SAR442168 compared to a daily dose of 14 mg teriflunomide (Aubagio) measured by annualized adjudicated relapse rate (ARR) in participants with relapsing forms of MS Secondary Objective: To assess efficacy of SAR442168 compared to teriflunomide (Aubagio) on disability progression, MRI lesions, cognitive performance …

teriflunomide
urine test
hmr1726
multiple sclerosis
serum pregnancy test
Investigational Site Number 8400001
 (5.8 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +3 other locations
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms

Psoriasis is a chronic, systemic, inflammatory disease in which skin cells build up and develop thick, red and white scaly patches on the skin. There is an unmet medical need for effective treatment in pediatric patients and this study is being done to evaluate risankizumab in pediatric participants with moderate …

inflammatory disease
risankizumab
ustekinumab
psoriasis
pediatric
Olympian Clinical Research /ID# 217941
 (5.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +8 other locations
Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Patients With COVID-19

This will be a phase 1a randomized, open label, multi-center study with approximately 24 subjects. All subjects will receive standard of care (SOC) per institutional guidelines for treatment of hospitalized patients with COVID-19 infection. In addition to SOC, the brequinar group will receive 5 daily doses of brequinar 100 mg.

throat
FIO2
pao2
malaise
cough
University of South Florida/Tampa General
 (7.7 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +3 other locations
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis

This is a Phase 3, multicenter, open-label, pharmacokinetics (PK)/safety study.The study consists of 3 periods:Screening period: 2 to 4 weeks.Treatment period: 24 weeks.Post-intervention follow-up period: 16 weeks. The study duration will be approximately 42 to 44 weeks for each participant (including screening, treatment, and follow-up periods).The total number of planned …

USF Health- Site Number : 8400003
 (7.7 away) Contact site
  • 0 views
  • 14 May, 2025
  • +5 other locations
The Positively Quit Trial for Smoking Cessation

The main goal of the present study is to determine if a smoking cessation program designed for people living with certain chronic conditions and delivered via videoconferencing groups works better than a control condition--a program that is not designed to help with smoking but that does have the same number …

University of South Florida, College of Public Health
 (9.4 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
Study to Evaluate the Safety Tolerability Pharmacokinetics and Efficacy of Remdesivir (GS-5734 ) in Participants From Birth to < 18 Years of Age With Coronavirus Disease 2019 (COVID-19)

The primary objectives of this study are to evaluate the safety, tolerability, and pharmacokinetics (PK) of remdesivir (RDV) in participants with laboratory-confirmed coronavirus disease 2019 (COVID-19) aged 0 days to < 18 years.

PCR test
SARS
covid-19
coronavirus infection
acute respiratory syndrome (sars)
Tampa General Hospital (Inpatient Visits)
 (7.7 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +7 other locations
A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

This is a Phase Ib/II study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia (ALL).

H Lee Moffitt Cancer Center
 (9.4 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +29 other locations